Health Care Efficiency Through Flexibility Act

HR5347, reported out of the House Ways and Means Committee on September 17, 2025, by a unanimous 43-0 vote, amends Section 1899(b)(3)(B) of the Social Security Act to require the Centers for Medicare & Medicaid Services to offer three specific collection types for quality measure reporting by ACOs in the Medicare Shared Savings Program for performance years 2025 through 2029: electronic clinical quality measures, MIPS clinical quality measures, and Medicare Clinical Quality Measures. The bill also clarifies data completeness rules, preventing CMS from deeming ACO data unrepresentative solely because it excludes data from one or more ACO participants. The bill remains awaiting floor action in the House with no companion bill introduced in the Senate. The money trail is absent. HR5347 contains no authorizations for spending, no appropriations, no tax credits, and no direct funding for any entity. It is a purely administrative bill that adjusts how existing quality reporting occurs under a program that is already operational. No new dollars flow to healthcare providers, technology vendors, or payers as a result of this legislation. The bill's impact is limited to regulatory compliance burden reduction for ACOs participating in Medicare Shared Savings. There are no structural winners or losers among publicly traded companies. Healthcare technology vendors that sell quality reporting software to ACOs (e.g., $HSTM, $EVH, $CERN as part of $ORCL) already support multiple collection types — this bill codifies existing CMS practice and does not expand the addressable market. Health insurers with Medicare Advantage or ACO exposure (e.g., $UNH, $HUM, $CVS) are unaffected because the bill applies only to program administration, not to payment rates, risk adjustment, or beneficiary access. No tickers meet the causal chain gate threshold because the policy lever does not create any revenue impact for any public company. No real market data was provided for analysis. The legislative timeline is uncertain: the bill cleared committee unanimously but requires a floor vote in the House and subsequent Senate action. Given the bill's narrow procedural nature, lack of controversial provisions, and bipartisan 43-0 committee vote, passage probability is moderately high but remains contingent on floor scheduling. No market-moving event is expected upon enactment.